Drug Profile
APP 103
Alternative Names: APP-103; APPTMLatest Information Update: 14 Sep 2023
Price :
$50
*
At a glance
- Originator Celdara Medical
- Class Anti-inflammatories
- Mechanism of Action Antioxidants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Reperfusion injury
Most Recent Events
- 13 Sep 2023 APP 103 is still in preclinical trials for Reperfusion injury in USA (Celdara Medical, pipeline, September 2023)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Reperfusion injury in USA
- 03 May 2017 Pharmacodynamic results from a preclinical trial in Reperfusion injury released by Celdara